Nonmyeloablative autologous peripheral blood stem cell transplantation for refractory autoimmune disease: 5-year follow-up
10.3760/cma.j.issn.1007-7480.2012.02.014
- VernacularTitle:非清髓性自体外周血造血干细胞移植治疗难治性自身免疫病五年随访
- Author:
Jingbo XU
;
Feng XIE
;
Wenzheng PANG
;
Shuping ZHONG
;
Xuegang LI
;
Jiangnan REN
;
Lijun HOU
- Publication Type:Journal Article
- Keywords:
Hematopoietic stem cell transplantation;
Lupus erythematosus,systemic;
Biomedical research
- From:
Chinese Journal of Rheumatology
2012;16(2):129-131
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the long-term efficacy of nonmyeloablative autologous peripheral blood stem cell transplantation(NAST) to cure refractory autoimmune disease(AD).MethodLong-term follow up of four cases of AD patients with NAST were summarized.The pretreatment regimen was intravenous injection of cytarabin (200 mg· kg-1· d-1 ) and cyclophosphamide (40 mg· kg-1· d-1).The therapeutic effect was evaluated by the change of symptoms and signs and long term complications.Changes of immune function were detected by flow-cytometry.ResultsFive cases of patients had been successfully engrafted.The average time for peripheral leucocytes count to reach 4.0×109/L was 12 days.It needed 10 days for platelets to return to 100×109/L and 22 days for hemoglobin to 120 g/L.Apparent remission of symptoms and signs was observed after transplantation.Lymphocyte subtypes analysis pre- and post- NAST showed that count of CD4+ and the ratio of CD4 +/CD8 + was returned to normal.One patient gave birth to a healthy baby four years after transplantation.Three female patients returned tonormal life. Conclusions Compared with classical myeloablative stem cell transplantation,NAST has a rapid hematopoietic recovery and good long-term therapeutic effect in AD.The quality of life in AD patients treated with NAST is higher than those treated with myeloablative hematopoietic stem cell transplantation.
